Labgenomics Co

Labgenomics Co Depreciation & Amortization

The Depreciation & Amortization of Labgenomics Co (084650.KQ) as of Nov 5, 2026 is 6.41 B KRW. In the previous year, Depreciation & Amortization was 3.04 B KRW — a change of 110.89% (higher).

Depreciation & Amortization

6.41 BKRW

YoY

110.89%

Last updated:

Depreciation & Amortization of Labgenomics Co is 2024 6.41 B KRW. Depreciation & Amortization of Labgenomics Co was 2023 3.04 B KRW. It decreases by 110.89% higher compared to the previous year.

The Labgenomics Co Depreciation & Amortization history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Depreciation & Amortization
Date
Depreciation & Amortization
Jan 1, 2017
260.00 M KRW
Jan 1, 2018
263.00 M KRW
Jan 1, 2019
868.00 M KRW
Jan 1, 2020
867.00 M KRW
Jan 1, 2021
965.47 M KRW
Jan 1, 2022
1.29 B KRW
Jan 1, 2023
3.04 B KRW
Jan 1, 2024
6.41 B KRW
The Labgenomics Co Depreciation & Amortization history
YEARDepreciation & AmortizationYoY
6.41 BKRW+110.89%
3.04 BKRW+135.98%
1.29 BKRW+33.45%
965.47 MKRW+11.36%
867.00 MKRW-0.12%
868.00 MKRW+230.04%
263.00 MKRW+1.15%
260.00 MKRW-28.77%
365.00 MKRW-10.10%
406.00 MKRW+3.57%
392.00 MKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Labgenomics Co Stock analysis

What does Labgenomics Co do? LabGenomics Co., Ltd. generates revenue through the provision of in vitro diagnostic (IVD) products and services. The company offers general diagnostic check services, molecular diagnostic check services, and research and development services, alongside IVD products such as DNA chips and PCR kits. Its diagnostic services include examinations for breast cancer and colorectal cancer, while its biosensor solutions target point of care testing (POCT). Additionally, LabGenomics sells healthy food as part of its product portfolio. The primary buyers of LabGenomics' services are healthcare institutions requiring diagnostic support, including hospitals and clinics. The company's molecular diagnostic services and cancer examinations are particularly sought after by medical facilities focused on specialized testing. Healthcare providers also purchase its biosensor solutions for immediate testing at the point of care. LabGenomics' product segments include IVD services, IVD products like DNA chips and PCR kits, cancer examination services, and healthy food. The company's molecular diagnostic services and cancer testing are key revenue drivers, while its biosensor for POCT and healthy food offerings serve complementary market segments. Labgenomics Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Labgenomics Co stock

Depreciation & Amortization of Labgenomics Co is 6.41 B KRW in 2024.

Depreciation & Amortization of Labgenomics Co changed from 3.04 B KRW to 6.41 B KRW, representing a 110.89% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Depreciation & Amortization Labgenomics Co since 2006 – with annual values, charts, and detailed analysis.

Depreciation & Amortization represents the allocation of the cost of tangible and intangible assets over their useful lives.

Depreciation & Amortization's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Depreciation & Amortization's Labgenomics Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — Labgenomics Co

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Labgenomics Co